Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

You may also be interested in...



U.K’s NICE To Help Build India’s Health Technology Assessment Board

India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.

Roche Experimenting With New Pricing Models In Oncology

Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.

Roche Experimenting With New Pricing Models In Oncology

Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel